Rhythm Pharmaceuticals (RYTM) Q2 FY26 earnings call

Rhythm Pharmaceuticals delivered a strong Q2 FY26, driven by the successful U.S. launch of IMCIVREE for acquired hypothalamic obesity, which saw robust patient demand and prescriber engagement. The company also reported encouraging Phase II data for its next-generation weekly MC4R agonist, RM-718, showing comparable efficacy to existing treatments without hyperpigmentation. Despite a one-time international revenue adjustment, the company maintains a solid financial position and is advancing its pipeline and global commercialization efforts.